PetVivo Holdings, Inc. (NASDAQ:PETV, PETVW))))) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals announced today it received a very favorable response from veterinarians regarding the Company's innovative product Spryng™, with OsteoCushion™ technology at the American College of Veterinary Surgeons ("ACVS") conference held on October 11th to October 14th, 2023 in Louisville, Kentucky.

 

SPRYNG™ with OsteoCushion™ Technology is an intra-articular injectable veterinary medical device consisting of sterilized, extra-cellular matrix microparticles; Spryng microparticles perform in the joint as wet, slippery micro-cushions used in the management of lameness and other joint related afflictions, such as osteoarthritis.

Two presentations at the ACVS Conference heightened the enthusiastic interest in veterinarians to learn more about Spryng and consider its use in their practices. The first presentation was given to an overflowing hall of veterinarians by Jessica Rychel, DVM, DACVSMR and Lindsey M. Fry, DVM, DACVSMR, CVPP, CCRP, cVMA, DVM, DACVSMR, CCRP, CVPP, cVMA, both founders of Red Sage Integrative Veterinary Partners; this presentation was entitled "When Surgery is Not an Option- a Multimodal Approach to Management of Orthopedic Cases". Joseph Manning, DVM, and Senior Technical Veterinarian for the Company, gave the second presentation related to the use of Spryng™ with OsteoCushion™ Technology entitled "Advancements in Intra-Articular Therapies: A Naturally Derived Option for Joints".

Finally, the Company released the completed results of a clinical study conducted by Ethos Veterinary Health at the ACVS annual conference; the clinical study examined the benefit and tolerability of an intra-articular injection of a collagen-elastin biomaterial (i.e. Spryng™ with OsteoCushion™ Technology) into the stifle joint of dogs with suspected cruciate ligament rupture. Dr. Erik Kleeman, DVM presented the clinical study poster at the ACVS Conference. The clinical study results demonstrated that there were significant improvements in all of the primary and secondary clinical variables throughout the study period (pain, lameness, quality of life scoring). In summary, this study demonstrated that Spryng™ is a reasonable, non-invasive alternative for patients with cranial cruciate disease ("CCD") when patient and/or owner factors preclude surgical intervention. To view the poster presentation and a video interview of Dr. Kleeman discussing the clinical study presented at the ACVS annual conference please visit the following:

https://www.sprynghealth.com/acvs-2023-poster-presentation?fbclid=IwAR3VuoyNy8wdqFnnArkNsjI-HzTXtXo49jDI3WOn8-835jMBf5spy451O6E

"The ACVS Conference provided us an excellent forum to demonstrate to leading veterinary surgeons our innovative medical device, Spryng, with OsteoCushion Technology, for the management of osteoarthritis" said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. "The conference resulted in us achieving our main objective, which was to explain to veterinarians that Spryng could be considered for first-line therapy in any animal, including those animals not able or willing to take oral medications and those not able or willing to undergo surgery."

For more information about PetVivo Holdings, Inc. and its innovative product, Spryng, please contact info1@petvivo.com or visit https://petvivo.com/ and https://sprynghealth.com/.